NCT06568692Phase 2Terminated

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Study sponsor: Processa Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-07-29Actual
Enrollment · participants20Actual
Source updated2026-10-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 90 participants (planned). After: 20 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2026. After: 29 Jul 2026.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source